Teleflex Says On March 11, Co, Acute Care And Urology Purchaser Received Request For Additional Information & Documentary Material From U.S. FTC; Acute Care And Urology Deal Anticipated To Be Completed In Second Half Of 2026

Original Equipment and Manufacturing and Development Services

As previously reported, on December 9, 2025, Teleflex Incorporated (the "Company") entered into an Equity Purchase Agreement (the "OEM Agreement") with Lotus US Bidco Inc. (the "OEM Purchaser"). The OEM Purchaser is a newly formed entity and an affiliate of Montagu Private Equity LLP and Kohlberg & CO., L.L.C.

The closing of the transactions contemplated by the OEM Agreement (the "OEM Transaction") is subject to customary conditions, including the expiration or termination of any waiting period applicable to the consummation of the OEM Transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act").

Effective as of 11:59 p.m. Eastern Time on March 13, 2026, the waiting period under the HSR Act with respect to the OEM Transaction expired, satisfying one of the conditions to the completion of the OEM Transaction.

The OEM Transaction is currently anticipated to be completed in the third quarter of 2026. The closing of the OEM Transaction remains subject to certain other regulatory approvals and conditions as set forth in the OEM Agreement.

Acute Care and Interventional Urology

As previously reported, on December 9, 2025, the Company also entered into an Equity Purchase Agreement (the "Acute Care and Urology Agreement", and together with the OEM Agreement, the "Agreements") with Intersurgical Limited (the "Acute Care and Urology Purchaser").

The closing of the transactions contemplated by the Acute Care and Urology Agreement (the "Acute Care and Urology Transaction") is subject to customary conditions, including the expiration or termination of any waiting period applicable to the consummation of the Acute Care and Urology Transaction under HSR Act.

On March 11, 2026, the Company and the Acute Care and Urology Purchaser each received a request for additional information and documentary material (each, a "Second Request") from the U.S. Federal Trade Commission (the "FTC") in connection with the FTC's review of the Acute Care and Urology Transaction. Issuance of the Second Requests extends the waiting period under the HSR Act until 30 days after the Company and the Acute Care and Urology Purchaser have each substantially complied with the Second Request it received, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. The Company and the Acute Care and Urology Purchaser have been working cooperatively with the FTC and will continue to do so.

The Acute Care and Urology Transaction is currently anticipated to be completed in the second half of 2026.The closing of the Acute Care and Urology Transaction remains subject to regulatory approvals and certain other conditions set forth in the Acute Care and Urology Agreement.

The OEM Transaction and the Acute Care and Urology Transaction constitute separate transactions which may be consummated independently from one another.